The earnings call highlighted significant revenue growth, new customer acquisitions, and a landmark partnership with AstraZeneca, reflecting positive business momentum. However, challenges remain with BioPharma headwinds, increased operating expenses, and regional performance issues in Latin America.

Company Guidance

During the SOPHiA GENETICS second-quarter 2025 earnings call, the company reported a 16% year-over-year revenue growth, with revenues reaching $18.3 million. Excluding the BioPharma sector, revenue saw a more substantial increase of over 20%. The company noted a significant milestone by signing 35 new customers to SOPHiA DDM in Q2, bringing the total to 63 new customers this year. In the U.S. market, revenue, excluding BioPharma, grew by more than 19%. The company also highlighted a major multiyear collaboration with AstraZeneca, touted as the largest contract in SOPHiA GENETICS' history, which is expected to drive future growth, particularly in 2026. The financial report also revealed a 35% year-over-year improvement in cash burn, which amounted to $8.7 million for the quarter, and an adjusted gross margin increase to 74.4%. The company reaffirmed its full-year revenue guidance of $72 million to $76 million, expecting continued robust growth in the clinical segment.

Revenue Growth and New Customer Acquisitions

Total revenue grew 16% year-over-year, with a 20% increase excluding BioPharma. The company signed a record 35 new customers in Q2, bringing the total to 63 new customers for the year.

Partnership with AstraZeneca

SOPHiA GENETICS signed the largest contract in its history with AstraZeneca, focusing on AI-powered predictive models and real-world evidence generation for breast cancer treatment.

U.S. Market Expansion

U.S. revenue, excluding BioPharma, grew more than 19% year-over-year. Notable new customers include UC Irvine and the University of Alabama, Birmingham.

Strong Performance in Asia Pacific

Asia Pacific region saw a 33% year-over-year revenue growth with significant contributions from markets like Australia and India.

Improved Gross Margin and Cash Burn

Adjusted gross margin improved to 74.4%, up 120 basis points year-over-year. Cash burn was reduced by 35% year-over-year, to $8.7 million.

SOPHiA GENETICS (SOPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SOPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.23 / -	-0.28	―	―	―
Aug 05, 2025	2025 (Q2)	-0.21 / -0.33	-0.23	-43.48% (-0.10)
May 06, 2025	2025 (Q1)	-0.22 / -0.26	-0.21	-23.81% (-0.05)
Mar 04, 2025	2024 (Q4)	-0.20 / -0.23	-0.37	37.84% (+0.14)
Nov 05, 2024	2024 (Q3)	-0.22 / -0.28	-0.21	-33.33% (-0.07)
Aug 06, 2024	2024 (Q2)	-0.27 / -0.23	-0.33	30.30% (+0.10)
May 07, 2024	2024 (Q1)	-0.24 / -0.21	-0.31	32.26% (+0.10)
Mar 05, 2024	2023 (Q4)	-0.22 / -0.37	-0.17	-117.65% (-0.20)	―
Nov 07, 2023	2023 (Q3)	-0.30 / -0.21	-0.3	30.00% (+0.09)	―
Aug 08, 2023	2023 (Q2)	-0.29 / -0.33	-0.39	15.38% (+0.06)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SOPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$3.30	$3.42	+3.64%
May 06, 2025	$3.14	$3.00	-4.46%
Mar 04, 2025	$3.57	$3.10	-13.17%
Nov 05, 2024	$3.75	$3.75	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does SOPHiA GENETICS (SOPH) report earnings?

SOPHiA GENETICS (SOPH) is schdueled to report earning on Nov 11, 2025, Before Open (Confirmed).

What is SOPHiA GENETICS (SOPH) earnings time?

SOPHiA GENETICS (SOPH) earnings time is at Nov 11, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SOPH EPS forecast?

SOPH EPS forecast for the fiscal quarter 2025 (Q3) is -0.23.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing